Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ITFG1 antisense RNA 1 (ITFG1-AS1), also known as lncRNA-ITFG1, is a long non-coding RNA (lncRNA) molecule. It is transcribed from the antisense strand of the ITFG1 gene locus and has been implicated in the regulation of various biological processes, especially cell proliferation. As a non-coding RNA, it does not encode a protein and its functional understanding primarily concerns gene expression regulation at the transcriptional and post-transcriptional level. While there is emerging evidence that some lncRNAs can impact cancer biology and other diseases, specific mechanistic and clinical details for ITFG1-AS1 remain limited[9][1][3][7]. There is no current evidence that ITFG1-AS1 acts as a therapeutic target (such as an enzyme, receptor, transporter, or ion channel) or that it is a direct target for any approved or experimental drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ITFG1 antisense RNA 1 (ITFG1-AS1).